We read with great interest the comments to our article 1 by Jha et al. 2 regarding the role of vascular endothelial growth factor (VEGF) and sVEGFR-2 in pre-eclampsia (PE). We agree with the observations made by Jha et al. that our data (with respect to VEGF) seem only apparently dramatically opposite and we would like to provide our view to explain these differences in the results and their interpretation.
In our article 1 a total of 540 pregnant women were enrolled and we evaluated the concentrations of VEGF and sVEGFR-2 by enzyme-linked immunosorbent assay analysis in gestational hypertension (GH, n ¼ 90), PE, (n ¼ 180), eclampsia (n ¼ 90) and control (n ¼ 180) pregnancy at different gestations and reported increased VEGF levels in PE and eclampsia. However, Jha et al. mentioned that in their investigations, they found undetectable circulating VEGF levels in PE/eclampsia. They have not mentioned the details of their enzyme-linked immunosorbent assay kit and the number of samples in which the analysis was done. Although, in our current publication, we have already mentioned that only controversial data are available with regard to gestational VEGF concentration in early and lateonset of pregnancy-induced hypertension patients. Several authors showed increased VEGF levels 3, 4 whereas others reported decreased VEGF levels in PE as compared with normal pregnant women. 5 Some studies could not report any differences between PE and normotensive pregnancies, as most of the concentrations obtained by analysis using a commercially available R&D ELISA kit (R&D Systems, Inc., Minneapolis, MN USA) were below detection limit. 6, 7 However, other laboratories using the same kit have reported lower concentrations in established PE as compared with normotensive pregnancies 5, [8] [9] [10] [11] whereas, others 12-14 using the same commercially available assay, actually found free elevated VEGF in established PE group. The differences in study design, limited statistical power and differences in population characteristics such as maternal age, race and ethnicity, severity of PE and gestational age of blood collection are likely to have contributed to the variability of results in various studies. Other technical differences in laboratory analytical procedures and reagents, 10 may also have contributed to inconsistencies in results. In our investigations, we measured free VEGF levels using commercially available ELISA kit (R & D systems) and observed that there was no change in VEGF levels in the control group, early weeks of GH and PE group, but these free VEGF levels were significantly elevated in late GH (P ¼ 0.0001), late PE (P ¼ 0.0001), and early (P ¼ 0.0001) and late (P ¼ 0.0001) eclampsia pregnant groups as compared with the control group, suggesting altered VEGF concentrations according to severity of these disorders. Our results corroborate to those studies that found significant increased circulating VEGF levels in PE compared with normotensive pregnancy (using the same commercially available assay), in established PE.
3,12-14 Indeed we are not the first authors reporting discrepancies in free VEGF levels in pregnancy-induced hypertensive disorders including PE patients.
The statement made by Jha et al. is true that a large number of studies, both experimental and human 9, [15] [16] [17] have shown consistent increase in sFlt-1 (sVEGFR-1) in PE patients. Similar observations were also observed by us in our previous study 18 where we reported that the serum levels of sVEGFR-1 were positively increased (Po0.0001) in patients with PE at different gestational intervals as compared with the healthy pregnant women. However, receiver operating characteristic curve analysis showed a higher sensitivity (89.17%), specificity (90.0%), area under the curve of 0.92 and concentration cutoff X15 855.8 pg ml À1 in early onset (p34 weeks) in contrast with the late-onset (434 weeks) pre-eclamptic group. Also, we have noticed similar kind of observations in gestational hypertensive and eclampsia groups as compared with normotensive pregnancies.
Several studies during pregnancy 9 suggest that the increased concentrations of sFlt-1 should be associated with decreased levels of free VEGF as it has been postulated that sVEGFR-1 interferes with VEGF signaling via direct ligand trapping, that is, effectively lowering free ligand concentrations available for receptor activation, and hence the function of sVEGFR-1 is supposed to be mainly inhibitory, complexing VEGF and acting as a regulator of VEGF bioavailability. In our experiments, we observed that there was a trend towards increased free VEGF levels along with sVEGFR-1 levels in the PE group. Thus, a positive correlation between sFlt-1 (sVEGFR-1) and VEGF observed suggests that sVEGFR-1 does not meaningfully influence circulating levels of free VEGF. It has been documented that the source of VEGF in pre-eclamptic women is mainly the placenta. 19 However, in our opinion, the increase of free VEGF circulating levels in PE are probably related to the hypoxic status of the placenta. Hypoxia induces binding of HIF-1a to the hypoxia responsive element in the VEGF gene promoter region, which in turn increases transcription of VEGF. 20 Hence, during placental hypoxia, these alterations in the transcription of VEGF may be associated with increased VEGF concentrations in the serum of pregnancy-induced hypertension patients (GH, PE and eclampsia). Its increased production could also be due to the extra-placental production like in endothelial cells of fetal or maternal vascular system, macrophages or in smooth muscle cells.
14 However, VEGF concentrations may also be altered secondary to renal dysfunction, alterations of other organs and cell activation. [21] [22] [23] [24] [25] Moreover, the degree and extent of organ damage in disease states may account for the variability of VEGF concentrations in serum.
PE causes hypertension, proteinuria and renal dysfunction on the maternal side, and growth retardation on the fetal side, often resulting in the artificial termination of a pregnancy. Recent clinical study has evaluated plasma levels of sVEGFR-2 as a potential surrogate biomarker of disease progression in various malignancies. 26 Like malignancies, pregnancy-induced hypertensive disorders including PE are a disease of abnormal angiogenesis. There are clinical studies on sVEGFR-2 as a surrogate biomarker for PE patients, 27 but there is a lack of data available examining the relationship between sVEGFR-2 and progression of pregnancy-induced hypertensive disorders from GH to eclampsia or the underlying factors governing in vivo modulation. Therefore, we evaluated sVEGFR-2 as a diagnostic marker in 540 pregnant women for the early diagnosis of various hypertensive disorders. The utility of this molecule is based on the hypothesis that circulating sVEGFR-2 levels may provide insight into VEGFR-2 expression and activation, a critical process in normal and abnormal angiogenesis as sVEGFR-2 may serve as an indicator of VEGFinduced VEGFR-2 receptor downregulation.
Our result is in contrast to a study by Masuyama et al. 28 reporting no significant difference in the mean serum concentration of sVEGFR-2 between patients diagnosed with PE and women with normal pregnancies. However, only 15 patients were included in that study. Our findings are partially consistent with the study conducted by Chaiworapongsa et al., 27 which showed that patients in early (p34 weeks) and late onset (434 weeks) PE group had a much lower median serum sVEGFR-2 concentration as compared with their respective controls. In this cross-sectional study, we extend their observation by determining sVEGFR-2 concentration at the early (p34 weeks) and late (434 weeks) onset of different clinical severity of hypertensive disorders and noticed that these levels were significantly reduced in early onset (p34 weeks, P ¼ 0.0001, P ¼ 0.0001, P ¼ 0.0001) and late onset (434 weeks, P ¼ 0.0001, P ¼ 0.0001, P ¼ 0.0001) of GH, PE, and eclampsia groups as compared with their respective controls. Although it was previously shown that sVEGFR-2 can bind to VEGF, 29 it remains unknown whether sVEGFR-2, like other soluble receptors such as sVEGFR-1, 30 can bind and sequester VEGF in vivo, thereby influencing binding and activation of VEGFR-1. Our results suggest that the decrease of sVEGFR-2 levels is inversely proportional to the progression of clinical severity of hypertensive disorders (GH to eclampsia) during pregnancy indicating its potential role in the pathogenesis of these disorders. This decrease in serum sVEGFR-2 concentrations is unlikely to be explained by an increased binding of sVEGFR-2 to VEGF as there is an abundance of sVEGFR-1, which has a much higher affinity to VEGF than sVEGFR-2. The low serum sVEGFR-2 concentrations in these disorders could be explained by the VEGF-induced downregulation of VEGFR-2 receptors as serum-free VEGF concentrations in PE are higher than those in normal pregnancy. Ebos et al. (2008) 31 also showed that VEGF-mediated VEGFR-2 downregulation from the cell surface, leads to reduced sVEGFR-2 levels in conditioned media from endothelial cells of tumor, showing that the expression level of VEGFR-2 and its soluble form is linked together. Hence, our results also support that sVEGFR-2 levels reduction may be induced by VEGF-mediated receptor downregulation in hypertensive disorders and suggest that sVEGFR-2 may serve as an indicator of VEGFinduced VEGFR-2 receptor downregulation. Therefore, in this study, reduced levels of sVEGFR-2 in hypertensive disorders may serve as an indicator of their respective cell surface receptors. This decreased VEGFR-2 receptor on cell surface may be due to the increased availability of cell surface VEGFR-1 receptor, which modulates VEGFR-2 due to its VEGF trapping ability. 32 Hence, serum sVEGFR-2 could be a surrogate marker of endothelial cell function in the maternal circulation, as VEGF signaling through VEGFR-2 is essential for endothelial cell function and survival. 33 However, future prospective clinical studies are needed to determine the alterations in these angiogenesisrelated molecules.
In our study we have mentioned that the lower sVEGFR-2 serum concentrations in patients with PE might reflect low regenerative capacity of endothelial cells. 34 It may be due to lower number of circulating endothelial progenitor cells, which have been proposed to reflect the regenerative capacity of endothelial cells. 35 Consistent with this hypothesis, several lines of evidence suggest that patients with hypertensive disorders, especially in the early onset group, have an increased risk of developing cardiovascular disease (CVD). 36 Hence, these patients were more susceptible to low regenerative capacity for endothelial cells, and thus, might be at risk for CVD. Also, recent data suggest that increased VEGF could actually worsen vascular disease by promoting neoangiogenesis. Because alterations in angiogenesis are associated with CVD, 37 these alterations would be evident in postpartum women with a history of PE before the development of hypertension or CVD.
In summary, for a successful pregnancy, there needs to be a balance of pro-and anti-angiogenic proteins that are made by the placenta. Understanding of the regulation of above proteins in pregnancy will only help to clarify the pathogenesis of PE. We don't think the use of sVEGFR-2 to differentiate different hypertensive disorders of pregnancy and its role in the pathogenesis of PE is overinterpretation of our findings as mentioned by Jha et al. The identification of the circulating factors such as sFlt-1 (sVEGFR-1) and sVEGFR-2 may mediate the maternal syndrome of PE in experimental animals and raises the possibility that pharmacologic strategies aimed at altering sFlt-1 and sVEGFR-2 might ameliorate the clinical disease. Further extensive studies are needed to better define the complex role of VEGF and its receptors in hypertensive disorders during pregnancy with due regard to maternal and child health.
